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Abstract
As life expectancy is projected to increase in the ensuing decades, individuals of older 
age continue to exceed the previous generation’s lifespan. Advancing age is associated 
with a reduction in physical and mental functional capacity, and chronic inflammation is 
a major factor contributing to this decline. A heightened inflammatory state can lead to 
exhaustion, weakness, weight loss, slow gate speed, and an overall decrease in activity 
level. These phenotypes define the onset of the disease process known as frailty. Frailty 
is a growing epidemic, which severely undermines a person’s ability to deal with out-
side stressors, and increases their rate of hospitalization, institutionalization, and mor-
tality. Current interventions focus on preventative care by improving exercise capacity, 
strength, nutritional supplementation, diet, and mobility. However, a biological cure has 
heretofore remained elusive. Here, we introduce the novel therapeutic principle that mes-
enchymal stem cell (MSC) therapy may represent a safe, practical, and efficacious both 
the treatment and prevention of frailty in individuals of advancing age. To date, a phase 
I safety trial reveals an excellent safety profile and suggests that mesenchymal stem cells 
can ameliorate signs and symptoms of frailty. These early studies lay the groundwork for 
future large-scale clinical trials of this exciting and novel therapeutic concept that has the 
potential to expand health span in the aging population.
Keywords: mesenchymal stem cells, immunomodulation, frailty, tumor necrosis 
factor-alpha, regenerative medicine
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1. Introduction
Projected life expectancy continues to grow worldwide owing to the advancement of new 
treatments and technologies for leading causes of death such as cardiovascular disease and 
cancer [1]. Meanwhile, frailty is gaining relevance as a significant clinical syndrome that is 
associated with increased risk of falls, depression, and disability, leading to higher mortality 
[2]. Frailty is defined by an age-related decline in reserve and function leading to a reduced 
ability to cope with acute or external stressors [3] and is characterized by easy tiring, decreased 
libido, mood disturbance, accelerated osteoporosis, diminished muscle strength, and suscep-
tibility to disease. However, the pathophysiology underlying this syndrome is complex and 
not clearly understood [4].
Inflammation is a pathophysiologic change that is closely linked with frailty [5]. Aging is asso-
ciated with immunosenescence or the dysregulation of the innate immune system, resulting 
in an increase of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleu-
kin (IL)-6, and IL-1β, further leading to a chronic low-grade inflammatory state [6]. Chronic 
inflammatory response inhibits the repair, turnover, and adaptation of many tissues, includ-
ing skeletal muscle [6]. Regeneration of skeletal muscle involves the cross-talk of muscle cells 
with immune cells, where the pro-inflammatory phenotype of immune cells promotes migra-
tion of satellite cells to the injured area, activates satellite cells, and matures newly formed 
muscle fibers [7]. Muscular degeneration caused by the altered pro-inflammatory state in frail 
patients is referred to as sarcopenia, another critical physiologic component of frailty.
Aging also produces physiologic changes in the brain, contributing to the development of 
frailty. Neurons with high metabolic demands, such as the hippocampal pyramidal neurons, 
are an important mediator in the pathophysiology of cognitive decline and are a key compo-
nent of the stress response [3]. Concomitant with changes in the immune system, microglial 
cells, which are the resident immune cells of the central nervous system, are also structur-
ally and functionally altered with aging and undergo senescence, likely causing damage and 
neuronal death [8]. Accumulating evidence supports an association between frailty, cognitive 
impairment, and dementia [9, 10].
The brain and endocrine system are intrinsically linked through the hypothalamo-pituitary 
axis, controlling metabolism via a series of homeostatic hormones. Four major circulating 
hormones are affected by aging: first, the decrease of insulin-like growth factor 1 (IGF-1) is 
associated with lower strength and decreased mobility [11]. Second, decreased sex hormone 
(estradiol and testosterone) increases the release of luteinizing hormone and follicle-stimu-
lating hormone [12]. Third, decreased activity of the adrenocortical cells produces the major 
sex steroid precursor dehydroepiandrosterone sulfate (DHEA-S), which is associated with a 
gradual rise in cortisol. DHEA-S directly maintains muscle mass and indirectly prevents the 
inflammatory pathways that contribute to muscle decline [13, 14]. Finally, the reduced level 
of 25(OH) vitamin D is associated with the development of osteoporosis [15].
Due to the complexity of multiple inter-related physiological systems that contribute to frailty, 
there is no gold standard for diagnosing the syndrome. There are currently two models for 
evaluating frailty: the phenotype model and the cumulative deficit model that forms the basis 
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of the Canadian Study of Health and Aging (CSHA) frailty index [16]. The phenotype model 
defines frailty as meeting three or more of five criteria: weight loss (>5% of body weight in the 
previous year), exhaustion (positive response to questions regarding effort required for activ-
ity), weakness (decreased grip strength), slow gait speed (>6–7 seconds for walking 15 feet), 
decreased physical activity, or low energy expenditure (kcal spent per week: males expend-
ing <383 kcal, females expending <270 kcal) (Table 1) [17]. This model is simple and easy to 
use; however, it fails to include factors such as cognitive impairment and highly prevalent 
conditions associated with functional decline and disability [3].
The cumulative deficit model is based on the accumulation of illnesses, functional and cogni-
tive declines, and social situations that are added together to calculate frailty [16]. This model 
utilizes 20 or more medically and functionally related questions and 92 baseline variables. The 
deficit model fashioned the origin of the CSHA frailty index [3]. The frailty index measures a 
number of age-associated health deficits (signs, symptoms, and laboratory values) [18], which 
is calculated by dividing each ‘deficit’ by the total number tested [3]. The higher the number 
of deficits, the higher the score, with ‘1’ being the maximum index, which indicates a poorer 
prognosis. Specifically, Rockwood and Mitnitski noted that an index >0.7 indicates a high risk 
of mortality [19]. In an effort to simplify this index, the same authors proposed the CSHA 
clinical frailty score, a 7-point rapid screening tool that was highly correlated with the frailty 
index; with 7 being the maximum score, indicating “severe frailty” [20]. The clinical frailty 
score is currently widely used in clinical practice [21].
2. Epidemiology
Universal characteristics that are associated with an increased prevalence of frailty include: 
chronological age, female sex, racial, and ethnic minority, those in supportive residential settings, 
and lower income [22]. The prevalence among community-dwelling people over 65 years of age 
Frailty phenotypes MSC response Postulated mechanism of action
Weight loss Maintains total caloric expenditure ↓ Inflammation which suppresses the onset of 
sarcopenia
Exhaustion ↑ Pulmonary function, ↓ chronic 
inflammation
↑ Endothelial function, ↓ markers of inflammation
Weakness ↑ Physical performance ↑ Mitochondrial transfer, ↑endogenous stem cell 
function
Slow gate speed ↑ 6-minute walk distance ↑ Endothelial function, ↑ cardiac performance, 
↑skeletal muscle performance
Decreased activity level ↓ Chronic inflammation, ↑ quality 
of life
↓ TNF-α, ↓ IL-1β, ↑ IL-10
Notes: MSCs home to sites of injury and to enhance repair of damaged tissue (heart, joints, muscle, and blood vessels) 
and exert their regenerative effects via paracrine signaling, mitochondrial transfer, direct cellular contact, and exosome 
excretion.
Table 1. The effect of MSCs on the phenotypes of frailty.
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ranges from 4 to 17% in studies with varying geographic features [23, 24]. There are similar trends 
in Japan, the country with the highest life expectancy in the world. The reason for longevity in 
Japan is multifactorial. The universal health insurance system, the high population density with 
close access to hospitals, fish-based diets, awareness of healthy aging in the general public, and 
lower prevalence of lung cancer despite a higher population of smokers are some contributors 
[25]. Interestingly, a meta-analyses of frail Japanese patients using the phenotype model dem-
onstrated that the age-stratified-weighted prevalence of frailty was lower in younger age groups 
(1.9% in 65–69 years, 3.8% in 70–74 years), the same in the 75–79-year age groups (10.0%), but 
higher in older age groups (20.4% in 80–84 years, 35.1% in ≥85 years) when compared to Western 
countries [25]. One explanation is that non-Japanese frail older individuals die younger, while 
Japanese frail older individuals survive longer, leading to a higher prevalence of frailty in their 80s.
3. Intervention and preventive care
While there is no cure for frailty, exercise is considered the most effective intervention to 
improve quality of life and functionality in frail adults. Improvements in muscle strength and 
mobility [26, 27] are among the most successful changes reported. Several studies have dem-
onstrated an improvement in muscle strength in older persons with resistance exercise [28–30]. 
A longitudinal study of aging showed that physical activity is associated with a slower pro-
gression in functional limitations in older adults over a follow-up period of 6 months [31]. 
A randomized, placebo-controlled trial compared resistance exercise training, multinutrient 
supplementation, both interventions, and neither intervention (control group) in frail adults 
over a period of 10 weeks. The study suggested that high-intensity resistance exercise train-
ing improved muscle strength, gait velocity, and stair-climbing power. However, nutritional 
supplementation did not reduce muscle weakness or physical frailty [28]. Similarly, the LIFE-P 
(lifestyle interventions and independence for Elders pilot) exploratory study demonstrated that 
regular physical activity reduces frailty prevalence at a 12-month follow-up time point [32].
Another approach to delay frailty is the use of nutritional supplements, which increase pro-
tein and caloric daily intake. Administration of leucine-enriched essential amino acids can 
increase muscle synthesis through stimulation of the mechanistic target of rapamycin (mTOR) 
signaling pathway [33]. The PROT-AGE study [34] reviewed the dietary protein intake in 
older healthy people (>65 years). They found that the optimal protein intake in older persons 
with sarcopenia is 1.0–1.2 g/kg body weight per day, and higher protein intake >1.2 g/kg body 
weight per day for those who are exercising. The PROVIDE trial [35] assessed protein supple-
ments enriched in leucine and vitamin D in sarcopenic older adults at high risk for disability. 
The study demonstrated that the group receiving high quantity protein supplements gained 
significantly more muscle mass and improved their chair stand ability relative to the control 
group.
The randomized Controlled Trial of Community-based Nutritional, Physical and Cognitive 
Training Intervention Programmes for At Risk Frail Elderly (FIT) compared the effects of 
6-month interventions with either nutritional supplementation, cognitive training, physi-
cal activity, the combination treatments, or no intervention (control) in prefrail and frail 
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adults [36]. Frailty score and status were measured at 3, 6 and 12 months. While these param-
eters were reduced in all groups, including the controls, the other four groups were signifi-
cantly improved compared to the controls, at all three time points. However, none of the 
interventions improved the secondary endpoints, which included: hospitalizations, falls, and 
performance of activities of daily living [36]. Recent studies suggest that vitamin D plays a 
role in the pathogenesis and management of frailty [37, 38]. One such study demonstrated 
that daily doses of ≥800 IU of vitamin D has beneficial effects on balance and muscle strength 
[39]; while another reported an improvement in balance with a single large dose of vitamin 
D [40]. While an analysis of 53 trials showed that vitamin D supplementation alone does not 
prevent fractures in older adults [41], supplementation of vitamin D in combination with 
calcium can prevent disabling hip fractures among others [41].
While diet and exercise have been thoroughly evaluated, hormone therapy has also been 
tested. Testosterone undecanoate plus a high-calorie supplement (2108–2416 kJ/day) was 
compared with a control group (placebo plus a low-calorie supplement (142–191 kJ/day)) 
in a randomized controlled trial. The results showed that there were no significant differ-
ences in frailty scores at either 6- or 12-month follow-up between the groups [42]. While 
testosterone treatment improves muscle strength, it also increases incidence of adverse car-
diovascular events [43]. Estrogen in combination with progestin therapy in postmenopausal 
women increases the risk of incident breast cancer after 5.6- or 7.1-years of follow-up [44, 45]. 
Likewise, the benefits of dehydroepiandrosterone sulfate (DHEA-S) supplementation in frail 
patients have not been demonstrated. Older subjects who received DHEA for 2 years exhib-
ited no beneficial effects on body composition, physical performance, or quality of life [46]. 
Similarly, 1 year of treatment with insulin-like growth factor 1 (IGF-1) did not alter bone min-
eral density, fat mass, muscle strength, blood lipid parameters, and measures of postprandial 
glucose disposal in postmenopausal women [47].
Frailty is increasingly recognized as a clinical state of vulnerability with increased risk of 
adverse health outcomes. The pathogenesis that underlies this syndrome is multifactorial 
and elusive, and there is not yet a gold standard for diagnosis or treatment. Exercise and 
nutritional supplementations are currently the key interventions for frailty. Although help-
ful, none of them have been proven to treat the disease process. Therefore, an alternative 
approach to treating frail adults needs to be investigated. Here, we focus on a novel interven-
tion, allogeneic mesenchymal stem cells (allo-MSCs) as a potential therapy for the treatment 
of frailty. While the mechanism is as yet unclear, we propose that the beneficial effects of 
MSCs for frailty are due, in large part, to a combination of their immunomodulatory, antifi-
brotic, and pro-regenerative effects.
4. Regenerative medicine
Frailty is a multifactorial condition triggered by genetic and environmental factors. As pre-
viously described, there is a direct association between frailty and the loss of proliferative 
homeostasis, neurodegeneration, DNA/mitochondrial mutations, free radical accumulation, 
a rise in pro-inflammatory markers, and increased immunosenescence. Stem cell depletion is 
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a key mechanism postulated to contribute to frailty and its epigenetic dysregulation [48–50]. 
Thus, the repletion of stem cells is an appealing approach to treat this multifactorial dysregu-
lation and MSCs are a particularly attractive candidate. MSCs are a multipotent, self-renew-
ing somatic progenitor cell type that exhibits immunoprivileged properties [51–53] and are 
relatively easy to collect (bone marrow harvest), isolate, and expand [54, 55].
MSCs home to sites of injury, upregulate endogenous stem cells, and reduce inflammation 
and organ dysfunction [56–61]. With respect to age-related diseases, MSCs have demonstrated 
improvements in ischemic and nonischemic cardiomyopathies [62–64], stroke [65], systemic 
inflammation [66], and Parkinson’s, among others [67]. Although not completely understood, 
the beneficial effects of stem cells are likely due primarily to paracrine signaling [68, 69] includ-
ing microvesicle/exosome release [70, 71] and secondarily to direct cellular contact including 
gap junction formation [72] and mitochondrial exchange via tunneling nanotubes [73, 60].
MSC effects at the molecular level are secondary to the secretion of growth factors, chemo-
kines, and metalloproteinases, including vascular endothelial growth factor (VEGF), angio-
poetin-1, fibroblast growth factor, placental growth factor, stem cell-derived factor (SDF), 
plasminogen activator [74], hepatocyte growth factor/scatter factor (HGF/SF) [75], secreted 
frizzled-related protein 2 (Sfrp2), hypoxic-induced Akt-regulated stem cell factor (HASF) and 
IGF-1 and -2 [76]. These molecules stimulate the Akt pathway [77], promote vasculogenesis 
[56], and protect native cells under hypoxic conditions [68]. In the heart, injection of MSCs 
produces antifibrotic, anti-inflammatory, and proangiogenic [57–59] effects and upregulates 
the proliferation of endogenous cardiac stem cells [60, 61], while improving the preservation 
of function of the cells surrounding the sites of injection.
MSCs mediate metabolic changes and stimulate resident cell activation after injury. In vitro 
studies have shown that MSC-conditioned culture media stimulates resident cardiac stem 
cells to proliferate, differentiate, and migrate [53, 78] via IGF-1. HASF and Sfrp2 prevent car-
diomyocyte apoptosis, promote cardiac stem cell differentiation, and reduce fibrosis after 
myocardial infarction (MI) [79–81].
The absence of major histocompatibility complex (MHC) class II antigens underlies the lack 
of allo-MSCs to stimulate a major immune response [82] and has generated an interest in their 
systemic and local application without the need for immunosuppression [62]. In the clinical 
setting, multiple trials have evaluated and proven the safety and efficacy of MSC therapy [63, 
64, 83–85]. Several disease processes have been studied in humans: autoimmune diseases, 
organ transplantation, and as a therapeutic agent after solid organ injury.
5. Immune biomarkers in aging and frailty
Aging and frailty are associated with a dramatic impairment of the ability of the immune 
system to provide protection from new pathogens. Older frail individual has serious com-
plications that cause adverse health outcomes including acute illness, heightened inflam-
matory state, and immune dysregulation, which cause a severe impairment in both innate 
and adaptive immunity and greater susceptibility to infectious diseases, comorbidities, and 
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increased mortality [86, 87]. The accumulation of reactive oxygen species (ROS) in the aging 
process leads, in part, to chronic activation of Toll-like receptors (TLRs), which in turn leads 
to an increase in the inflammatory process [88–90]. In frailty, the immune phenotype is dys-
regulated due to incrementing chronic inflammation known as inflammaging and includes 
increased IL-6, C-reactive peptide (CRP), and TNF-α [87]. Inflammaging plays an important 
role in the suppression of the immune system and the remodeling of the immune phenotype 
(Figure 1). The remodeling of the immune phenotype in aging is known as immunosenes-
cence and is marked by several immune biomarkers described below.
The immune risk phenotype (IRP), which is the ratio of CD4+ to CD8+ T cells, decreases to 
<1 in aging and frailty, has been linked to increased risk of mortality [91, 92]. The decreased 
IRP associated with aging and frailty is due to an expansion of the CD8+ compartment in 
comparison to the CD4+ compartment. In spite of the expansion of the CD8+ T-cell compart-
ment, the effector T cells in frail individuals have diminished function mostly due to antigen 
experienced CD8+ T cells re-expressing the naïve marker CD45RA, also known as TEMRA 
T cells [87]. This expansion of the TEMRA T cell population is exacerbated by factors such 
as chronic activation due to Cytomegalovirus (CMV) exposure known to be present in >60% 
of the US population [93]. Finally, the ability to produce protective antibodies upon new 
antigenic exposure is also severely impaired in aging and frailty due to a remodeling of 
the B cell compartment. In addition, there is an intrinsic defect in B cells in aging, which 
causes a decrease in the enzyme, activation-induced cytidine deaminase (AID) leading to 
diminished ability to switch antibody isotype, which has been correlated to increased TNF-α 
[94]. The inflammaging process depletes the B cell compartment of switched memory B cells, 
which are a predictive biomarker for protective vaccine response. In addition, the refractory/
exhausted B cell compartment is expanded filling up the B cell niche with unresponsive cells 
[86, 94, 95].
Figure 1. The role of stressors, aging, and inflammation in frailty and the effects of mesenchymal stem cells. As 
individuals grow older, several stressors (poor nutrition, diseases, oxidative stress, and environmental factors) increase 
the inflammaging process leading to frailty. Mesenchymal stem cells (MSCs) secrete several factors that block or reverse 
the inflammaging process and ultimately reverses the effects of frailty.
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6. The role of MSCs in inflammaging and immune modulation
Human bone marrow-derived MSCs downregulate the expression of pro-inflammatory cytokines 
TNF-α, IL-1β, IL-6, and monocyte chemoattractant protein-1 (Figure 2) [96, 32]. Other immuno-
modulatory properties include the inhibition of dendritic cells, natural killer cells [97–99], and 
T/B cell proliferation via the downregulation of the molecules programmed death-1 (PD-1) trans-
forming growth factor-β, HGF, nitric oxide, indoleamine 2,3-dioxygenase, and prostaglandin-E2 
release [52, 68]. Interestingly, MSCs are able to transform pro-inflammatory macrophages (M1) 
into anti-inflammatory macrophages (M2) by upregulating IGF-1 and IL-10 [100], thereby pro-
moting angiogenesis and cardiomyocyte recovery [101, 102]. Most importantly, MSCs suppress 
T cell activation, which is crucial due to the high incidence of CMV virus among the US popula-
tion, causing chronic activation of T cells leading to an exhausted immune phenotype [103].
Ground-breaking immune-modulatory results in the Randomized Comparison of Allogeneic 
Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: 
POSEIDON-DCM study demonstrated that 6 months post-TESI, allogeneic human mesen-
chymal stem cells (hMSCs) were more efficient than auto-hMSCs in reducing serum levels 
of TNF-α, increased switched memory B cells, decreased exhausted B cells concomitant with 
a decrease in the percentage of B cells expressing TNF-α, decreased T cell activation and 
decreased TEMRA T cells [62]. This reversal on the effects of chronic inflammation on these 
immune biomarkers opens up the feasibility of using allo-hMSC as a treatment to reverse the 
process of inflammaging and immunosenescence.
Together, these findings are indicative of the safety of MSC therapy in a variety of disease pro-
cesses. Furthermore, given that MSCs are known to elicit immunomodulatory, neoangiogenic, 
MSCs
Reduces Inflammation:
TNF-α, IL-1β, IL-6 
Figure 2. MSCs serve as an anti-inflammatory treatment. (A) Depiction of systemic inflammation (white asterisks’). 
(B). The anti-inflammatory effects of MSCs. Reproduced from Golpanian et al., with permission from the publisher.
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endogenous cellular proliferative, and antifibrotic effects post-MI in both animal models and 
clinical trials alike, we anticipate that MSC therapy will act in a similar manner and prove 
beneficial in older individuals with frailty.
7. CRATUS phase I and II
The therapeutic interventions available to frail older individuals focus on improving the 
functionality of a precipitously declining quality of life. With the understanding that dete-
riorating endogenous stem cell function is a key mechanism behind this disease process, 
the allogeneic human mesenchymal stem cells (allo-hMSC) in patients with aging FRAilTy 
via intravenous delivery (CRATUS) trial (Figure 3) was established to reverse the untoward 
effects of frailty. Conducted at the University of Miami Miller School of Medicine, the pilot 
phase was designed to establish an optimal dose, and tested the hypothesis that allo-hMSCs 
were safe, well tolerated, and reduced the signs and symptoms of the disease [104]. The study 
was conducted in a nonrandomized, nonblinded, escalating dosage via peripheral intrave-
nous infusion in 15 frail subjects [104]. Donors were healthy males and females between 
the ages of 20 and 45 [104]. Three groups of five patients each received either 20 million 
(M)-, 100M-, or 200M-cells [104]. Patients were followed out to 1-year postinfusion. The pilot 
phase revealed the two most salient doses (100M- and 200M-cells) [55] and was followed by 
Group 1: 
20 million MSCs 
(single i.v. infusion) 
Group 2: 
100 million MSCs 
(single i.v. infusion) 
Group 3: 
200 million MSCs 
(single i.v. infusion) 
Phase 1:  “Run In” Safety Phase
Primary Endpoint: Safety of single infusion
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n=10
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Phase 2:  Safety & Efficacy
Primary Endpoint:  Safety
Screening
•Aging Frailty 
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•≥ 60 and ≤ 95
• MMSE Score ≥ 24
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12 month Safety
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1, 3 & 6 months
Safety 
& 
Efficacy 
Evaluaons
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Phase 2 Study Iniated in new 
subjects aer Phase 1 six month me 
point in last paent at highest dose.
Figure 3. Schematic of the CRATUS pilot and randomized phases.
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phase II, a randomized, double-blinded, placebo-controlled trial that further tested the safety 
and efficacy of allo-hMSCs in frail older individuals.
7.1. Results of the phase I study
The 15 subjects in the pilot phase had an average age of 78.4 ± 4.7 years [55]. Eight patients 
were categorized as vulnerable to frailty with a CSHA score of 4 and the others were mild, 
with a score of 6 (n = 6) and moderate with a score of 7 (n = 1) [55]. Most importantly, the 
primary endpoint, treatment-emergent serious adverse events (TE-SAE) at 1-month postinfu-
sion, was met with no adverse reactions in any group [55].
Efficacy outcomes were measured out to 6 months postinfusion as a secondary endpoint. 
The 6-minute walk distance (6-MWD) test is a measure of functional exercise capacity [105], 
which can reflect a frail subject’s ability to perform basic activities of daily living. The test has 
been specifically used to assess subjects with diseases of the musculoskeletal, pulmonary, and 
cardiovascular systems [106–108]; and as such, the subjects experienced a significant improve-
ment in all treatment groups at 3 and 6 months postinfusion with the greatest improvement 
in the 100M cell-dose group in the phase I [55]. Pulmonary function was measured via FEV1, 
and improved in the 200M cell-dose group [55]. In regard to physical and quality of life 
improvement, the SF-36 questionnaire, which has a physical and mental component, yielded 
an improvement in the 100M-group in the pilot phase. Immunomodulation was also reported 
with a significant reduction in the pro-inflammatory biomarker serum TNF-α in the 100M 
and 200M cell-dose groups at 6 months postinfusion [55].
7.2. Update on the phase II study
The 30 subjects in phase II had a mean age of 75.5 ± 7.3 and a mean frailty score of 4 based on 
the CSHA Clinical Frailty Scale, and were equally randomized to receive 100M-, 200M-cells, 
or placebo [109]. Safety was the primary endpoint of the study and was measured via the 
occurrence of TE-SAE at 1-month postinfusion. The trial has completed enrollment, however, 
as reported in phase 1, preliminary findings show that the treatment is safe and produces sig-
nificant improvements in the treated subjects in both quality of life and functional status [109].
8. Conclusion
Frailty has increasingly been recognized as a constellation of waning physical and mental 
qualities secondary to outside stressors, which relate to aging, and confer a vulnerability to 
adverse health outcomes [110]. Biologically, inflammation and stem cell depletion are at the 
forefront of this disease process. Early intervention is warranted at the onset of recognized 
symptoms to reduce the burden of disease progression, hospitalizations, and associated 
healthcare costs [111, 112]. To date, several important multimodal interventions are available 
to manage frailty; however, a disease-specific treatment has yet to emerge [112, 113]. Given 
the positive results of numerous studies utilizing MSCs in a variety of disease processes com-
mon to frailty as defined by the physical phenotype model, we believe stem cell therapy will 
be a treatment of choice for this disease process.
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Future implications of stem cell administration in frail or prefrail older individuals may 
be useful in settings where undo stress may cause rapid physical deterioration. There are 
a number of medical procedures (breast/colorectal cancer treatment, cardiac surgery, non-
cardiac elective surgery, etc.) that are taxing to a young healthy individual let alone older 
individuals [114–116]. A preemptive or perioperative administration of MSCs may dampen 
the immune response, aid in the healing process, and keep at-risk older individuals from 
declining in functional status (Table 2) [56, 117–120]. Given the results from the CRATUS, 
pilot dose finding [55] and randomized placebo controlled study [109] and the number of 
medical procedures older individuals undergo, large, randomized, double-blinded clinical 
trials are warranted to elucidate the efficacy of stem cell therapy in regard to the disease 
process in itself and its ability to suppress the progression of frailty after strenuous medical 
interventions.
In summary, allogeneic MSCs are immunotolerant in frail older individuals providing clini-
cally meaningful improvements in functional capacity, inflammatory biomarkers, and quality 
of life patient-reported outcomes. Frailty, the multimodal biologically mediated decline in 
physiologic reserve, may now have an optimistic therapeutic option.
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Future indications applicable to 
frailty
Response to MSCs Proposed mechanisms of action
Osteoporosis Improved bone mineral content and 
reduced rate of fractures
Reduction in ROS and increased 
AMPK
Heart disease Improved function Increased endothelial function, 
decreased inflammation, reduced 
cardiac fibrosis, and increased 
cardiomyogenesis
Delayed healing in Injury Increased wound healing Decrease inflammation (TNF-α and 
IL-1β), Increased IL-10
Autoimmunity Delayed onset/prevention Suppress TH17, induce T regs, and 
promote TH2 response
Table 2. MSCs and future indications.
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